Personalized cancer vaccine shows potential

Nine patients were cancer-free after three years, a small study on kidney cancer found

February 7, 2025 Check out STAT+

Sponsored By

Want unlimited access to our exclusive cancer coverage? Get 50% off your first year of STAT+ here.

PATRICK HERTZOG/AFP via Getty Images STAT+ | Personalized cancer vaccine shows potential in kidney cancer In the Phase 1 study, nine people with advanced kidney cancer became cancer-free after receiving personalized vaccines. By Elizabeth Cooney STAT+ | Merck's earnings miss focused attention on Gardasil. The real issue is Keytruda The cancer drug will lose its patent exclusivity in 2028. And it could face lower reimbursement from Medicare under the Inflation Reduction Act before that. By Matthew Herper STAT+ | Class action suit over UnitedHealth's AI care denials nears key moment Ruling may come this month on UnitedHealth's motion to dismiss lawsuit stemming from STAT reporting on firm's use of AI to cut off rehabilitative care. By Bob Herman Photo illustration: Christine Kao/STAT; Photos: Adobe STAT+ | The CRISPR companies are not OK Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR is hard to do profitably. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser